• J Craniomaxillofac Surg · Apr 2008

    Randomized Controlled Trial Comparative Study

    Postoperative nausea and vomiting after surgery for prognathism: not only a question of patients' comfort. A placebo-controlled comparison of dolasetron and droperidol.

    • Swen N Piper, Kerstin Röhm, Joachim Boldt, Peter Kranke, Wolfgang Maleck, Rudolf Seifert, and Stefan Suttner.
    • Department of Anaesthesiology and Critical Care Medicine, Klinikum Ludwigshafen, Germany.
    • J Craniomaxillofac Surg. 2008 Apr 1;36(3):173-9.

    IntroductionThe aim of this study was to evaluate the efficacy of dolasetron and droperidol (DHB) for preventing postoperative nausea and vomiting (PONV) in patients undergoing surgery for prognathism.Material And MethodsIn a randomised, placebo-controlled, double-blind trial, the efficacy of 12.5 mg dolasetron i.v. and 1.25 mg DHB was evaluated in preventing PONV in 83 patients undergoing surgery for prognathism. Patients were allocated randomly to one of three groups: group A (n=27) received 12.5 mg dolasetron intravenously (i.v.), group B (n=27) received 1.25 mg DHB i.v. and placebo group C (n=29) received saline 0.9%. If patients complained of retching or vomiting or if patients demanded antiemetics, 20mg metoclopramide (MCP) i.v. was given. Postoperative nausea, postoperative vomiting, or nausea and vomiting was assessed in the postoperative period at 0-4 h and overall between 0 and 24 h.ResultsA significant reduction in the incidence of postoperative nausea and/or vomiting was observed in the dolasetron group (33%) when compared with DHB (81%) and placebo (86%) treated patients. No other significant differences between the DHB and the placebo group were found. Dolasetron (11%) significantly reduced vomiting in comparison with the DHB (52%) and placebo group (52%). The use of postoperative MCP per patient was significantly lower in the dolasetron group when compared with both other groups. Dolasetron significantly reduced the postoperative nausea and/or vomiting-score when compared with both other groups. There was no significant difference between DHB- and placebo-treated patients with regard to nausea and/or vomiting.ConclusionIntravenous dolasetron (12.5 mg) is more effective than either intravenous DHB (1.25 mg) or placebo for preventing PONV after surgery for prognathism. It also was significantly superior to either DHB or placebo concerning nausea and vomiting and the need for MCP rescue medication.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…